Technology

Olix Pharmaceuticals, Inc. Expands Development of Adipose Tissue-Targeted Weight-Loss Drug… Plans to File IND Application in the First Half of Next Year

ALK7-Targeted ‘OLX501A’ Reduces Visceral Fat by 29% in Primate Trials Efforts Underway to Secure Data from Primate Trials of Terzepatide Combination Therapy by Early Next Year New Single-Target and Dual-Target RNAi Technologies Developed… Expanding the Pool of Obesity Drug Candidates

KIM SAE-MI
2026-11-16 16:35:03
[Edaily Reporter KIM SAE-MI ] RNA interference (RNAi) drug developer Olix Pharmaceuticals, Inc.(226950)is expanding its research and development of next-generation obesity treatments using adipose tissue-targeted RNAi technology.

Olix Pharmaceuticals, Inc. CI (Photo courtesy of Olix Pharmaceuticals, Inc.)

Olix Pharmaceuticals, Inc. announced on the 16th that it will strengthen research and development based on its “OASIS-Adipose” adipose tissue-targeting RNAi platform, drawing on global obesity treatment development trends identified at “BIO-Europe 2026,” held in Cologne, Germany, from the 9th to the 11th.

According to Olix Pharmaceuticals, Inc., recent global obesity drug development is expanding toward combination therapies that pair existing glucagon-like peptide-1 (GLP-1) class therapies with new drugs featuring different mechanisms of action, as well as the development of non-incretin drugs that differ from the incretin class. In particular, the company explained that ALK7 and INHBE-related pathways, which are involved in metabolic regulation in adipose tissue, are gaining attention as new targets for obesity drug development.

Earlier, global pharmaceutical company Roche signed a global exclusive technology licensing agreement last month for an ALK7-targeted RNAi obesity treatment developed by China’s Rona Therapeutics, worth up to $1.16 billion (approximately 1.7 trillion won). Olix Pharmaceuticals, Inc. is also developing an obesity treatment that utilizes the same ALK7 target.

Olix Pharmaceuticals, Inc.’s “OLX501A” demonstrated efficacy in previous non-human primate (NHP) trials, inhibiting ALK7 gene expression by 89% and reducing visceral fat volume by 29.2%. In a comparative trial presented by the company, a competing compound achieved an ALK7 expression inhibition rate of 88% and a visceral fat reduction rate of 10.0%.

Olix Pharmaceuticals, Inc. is proceeding with development with the goal of submitting an Investigational New Drug (IND) application for OLX501A in the first half of next year. The company is also conducting research on combination therapy with existing obesity treatments.

Previously, Olix Pharmaceuticals, Inc. explained that in an obese mouse model, the combination of OLX501A and the GLP-1/GIP dual agonist turzepatide demonstrated the potential to reduce body fat and mitigate the loss of lean body mass. Based on these findings, the company plans to collect and release data from non-human primate combination trials in early 2027.

The company is also pursuing the discovery of new targets and the development of dual-target technology. Olix Pharmaceuticals, Inc. has confirmed the efficacy of gene expression suppression and reductions in body weight and body fat in an obese mouse model for “Target X,” a new target other than ALK7, and is currently verifying the potential for further improvement in efficacy.

Furthermore, the company plans to expand its portfolio of obesity treatment candidates by developing the “OASIS-D-Adipose” technology, which simultaneously suppresses both target genes within adipose tissue.

Lee Dong-ki, CEO of Olix Pharmaceuticals, Inc., stated, “Through this year’s Bio Europe, we confirmed that interest in new mechanisms of action and combination therapies is growing in the next-generation obesity treatment market.” He added, “At this event, we held in-depth discussions with several potential partners regarding our R&D strategy for obesity treatments and opportunities for collaboration, and we are doing our utmost to ensure that these discussions lead to tangible results in technology transfer and partnerships.”

Economy

Corporation

IT·Science

Economy

A Plus Asset Reports Cumulative Operating Profit of 41.1 Billion Won for the First Three Quarters… Up 82% Year-Over-Year

General Insurance Agency (GA) A Plus Asset(244920)reported an 82% year-over-year increase in cumulative operating profit for the first three quarters of this year. Revenue and net income also posted d…
2026-11-16 16:41:49

Corporation

'Balanced Growth in Fashion and Beauty' LF Reports 51.1 Billion Won in Q3 Operating Profit… Up 217%

LF achieved both revenue growth and improved profitability in the third quarter, driven by balanced growth across its in-house and imported fashion and beauty brands. LF(093050)According to the quarte…
2026-11-16 16:38:14

IT·Science

VUNO, Inc. Narrows Third-Quarter Operating Loss to 2 Billion… Cost-Cutting Efforts Show Results

VUNO, Inc.(338220)has significantly reduced its third-quarter operating loss, signaling a path toward improved profitability. While the AI-based cardiac arrest prediction medical device “VUNO Med-Deep…
2026-11-16 16:47:02